On November 4th, the Sahin Lab embarked on a remarkable journey, cycling 10 miles to raise awareness for cancer in LOWVELO. The ride exemplified the profound impact that collective action can have in spreading awareness and advancing the cancer research and support.
“Hollings team marks milestone in progress toward investigational new drug for triple-negative breast cancer” https://hollingscancercenter.musc.edu/news/archive/2024/07/22/lox-inhibitor-for-triple-negative-breast-cancer
A highly potent bi-thiazole inhibitor of LOX rewires collagen architecture and enhances chemoresponse in triple-negative breast cancer https://www.sciencedirect.com/science/article/pii/S2451945624002733?via%3Dihub
We participated in the AACR conference with three distinct poster presentations.
0 Comments